全文获取类型
收费全文 | 2414篇 |
免费 | 205篇 |
国内免费 | 7篇 |
学科分类
医药卫生 | 2626篇 |
出版年
2023年 | 28篇 |
2022年 | 18篇 |
2021年 | 93篇 |
2020年 | 55篇 |
2019年 | 92篇 |
2018年 | 99篇 |
2017年 | 62篇 |
2016年 | 74篇 |
2015年 | 73篇 |
2014年 | 128篇 |
2013年 | 135篇 |
2012年 | 245篇 |
2011年 | 237篇 |
2010年 | 137篇 |
2009年 | 113篇 |
2008年 | 162篇 |
2007年 | 179篇 |
2006年 | 168篇 |
2005年 | 147篇 |
2004年 | 136篇 |
2003年 | 98篇 |
2002年 | 75篇 |
2001年 | 4篇 |
2000年 | 2篇 |
1999年 | 4篇 |
1998年 | 22篇 |
1997年 | 6篇 |
1996年 | 2篇 |
1995年 | 4篇 |
1993年 | 3篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1980年 | 1篇 |
1977年 | 1篇 |
1976年 | 2篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1972年 | 2篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1969年 | 2篇 |
1967年 | 2篇 |
1966年 | 1篇 |
1964年 | 2篇 |
1963年 | 1篇 |
1960年 | 1篇 |
1911年 | 1篇 |
排序方式: 共有2626条查询结果,搜索用时 46 毫秒
1.
2.
Norah Anthony Delphine Bourneau-martin Sarah Ghamrawi Laurence Lagarce Marina Babin Marie Briet 《Fundamental & clinical pharmacology》2020,34(6):736-742
Vitiligo is a common depigmenting disorder ensuing the loss of epidermal melanocytes. It is a multifactorial disease with immunological, genetic and environmental factors including drug exposure. The purpose of the study was to investigate the drugs and therapeutic subclasses associated with vitiligo occurrence reported in VigiBase®, the WHO pharmacovigilance database. A case/non-case study was carried out by defining cases as vitiligo reports and non-cases as all other reports. The reporting odds ratio (ROR) was calculated for the ‘suspected’ drugs and drug classes according to ATC level 4. During the study period, 741 cases of vitiligo were registered. Mean age was 49 ± 20 years. The disproportionality analysis showed an association between vitiligo and pembrolizumab (ROR 116.9, 95% Confidence Interval (CI) 94.8, 144.3), nivolumab (ROR 22.6, 95% CI 15.8, 32.4), ipilimumab (ROR 41.7, 95% CI 25.0, 69.7), imiquimod (ROR 152.8, 95% CI 103.0, 226.7), adalimumab (ROR 3.8, 95% CI 2.5,5.8), infliximab (ROR 2.6, 95% CI 1.65, 4.01), alemtuzumab (ROR 27.8, 95% CI 17.6, 43.9), and ustekinumab (ROR 9.3, 95% CI 5.6, 15.6). Concerning the pharmacological classes ATC level 4, a significant association was found with monoclonal antibodies, interferons, selective immunosuppressants, TNF-alpha inhibitors, interleukin inhibitors, and topical antivirals. This study confirmed the expected associations between vitiligo and immune checkpoint inhibitors and strengthened the emerging signal about the association between vitiligo and imiquimod, TNF-alpha inhibitors and interferons. New signals were shown with selective immunosuppressants including alemtuzumab and interleukin inhibitors. 相似文献
3.
4.
Jérôme Le Pavec Séverine Feuillet Olaf Mercier Pauline Pradère Gaëlle Dauriat Adrian Crutu Valentina Florea Laurent Savale Marilyne Levy Florent Laverdure François Stephan Dominique Fabre Mitilian Delphine David Boulate Sacha Mussot Sébastien Hascoët Damien Bonnet Marc Humbert Elie Fadel 《The Journal of heart and lung transplantation》2021,40(7):652-661
5.
Florent Maillet Dorian Wolff Angele Soria Frederic Adnet Virginie Panayotopoulos Delphine Gobert Frederic Lapostolle Paul‐Georges Reuter Aiham Ghazali Frederic Caux Olivier Fain Nicolas Javaud 《The Journal of dermatology》2019,46(5):383-388
The benefit of corticosteroids in acute urticaria is controversial. Our objective was to determine the factors associated with relapses in patients presenting with acute urticaria. A retrospective observational study, including all patients with acute urticaria who visited the angioedema reference center of Academic Public Hospitals – Saint‐Antoine in Paris between January 2015 and June 2017, was conducted. The study inclusion criterion was a diagnosis of acute urticaria in an adult patient. The urticaria was spontaneous or inducible urticaria. The primary outcome was relapse at day 7 and the secondary outcome was relapse at week 6. A total of 184 patients with a first episode of acute urticaria were included. Most of the patients were female (66%) with a mean age of 42 ± 16 years. Corticosteroid administration for treatment of acute urticaria was used in 102 (55%) patients. Overall, 85 (46%) patients had relapses after less than 7 days whereas 168 (91%) patients had relapses after more than 6 weeks. In univariate analysis, the rate of corticosteroid administration was significantly higher in cases of relapse after less than 7 days. No difference in relapse rates after more than 6 weeks appeared. In the multivariate analysis, the independent factor associated with relapses after less than 7 days was the administration of corticosteroids as treatment of acute urticaria (odds ratio, 1.93; 95% confidence interval, 1.06–3.57; P = 0.03). The prevalence of corticosteroid administration for patients with acute urticaria was high. Corticosteroid administration was an independent risk factor associated with relapses after less than 7 days. 相似文献
6.
7.
8.
9.
Jean‐Louis Dargent Stéphanie Henne Delphine Pranger Piera Balzarini Daniel Sartenaer Geneviève Bulliard Katrina Rack Fabio Facchetti 《Journal of cutaneous pathology》2016,43(3):280-286
Plasmacytoid dendritic cells (PDC) belong to a subtype of dendritic cells that are normally absent in healthy skin. In some inflammatory diseases of the skin, especially lupus erythematosus (LE), these cells are occasionally recruited in great amounts, which can be used as a helpful clue for diagnosis. Rarely, PDC may also accumulate in the skin of patients with myeloid leukemia, a yet poorly known condition currently called ‘tumor‐forming PDC associated with myeloid neoplasms’. In this study, we describe a patient with unsuspected chronic myelomonocytic leukemia who developed cutaneous lesions characterized by a dermal infiltrate rich in PDC. Similarly to LE, such neoplastic PDC were accompanied by interface dermatitis‐like changes, but displayed an aberrant phenotype and shared the same chromosomal abnormality with the leukemic cells identified in the bone marrow, thus revealing the neoplastic nature of the process. This observation illustrates that tumor‐forming PDC associated with myeloid neoplasms may microscopically mimic LE in some patients. Accordingly, a hematologic workup is recommended in any skin lesion featuring excessive numbers of PDC, even if morphological alterations suggestive of interface dermatitis are found. 相似文献
10.
Amélie Huynh Le Maux Bernadette Pignol Delphine Behr-Roussel Jean-Luc Blachon Pierre-Etienne Chabrier Sandrine Compagnie Philippe Picaut Jacques Bernabé Fran?ois Giuliano Pierre Denys 《Toxins》2015,7(12):5462-5471
Intradetrusor injections of Botulinum toxin A—currently onabotulinumtoxinA—is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO). The common clinical practice is 30 × 1 mL injections in the detrusor; however, protocols remain variable and standardization is warranted. The effect of reducing the number of injection sites of Dysport® abobotulinumtoxinA (aboBoNTA) was assessed in the spinal cord-injured rat (SCI). Nineteen days post-spinalization, female rats received intradetrusor injections of saline or aboBoNTA 22.5 U distributed among four or eight sites. Two days after injection, continuous cystometry was performed in conscious rats. Efficacy of aboBoNTA 22.5 U was assessed versus aggregated saline groups on clinically-relevant parameters: maximal pressure, bladder capacity, compliance, voiding efficiency, as well as amplitude, frequency, and volume threshold for nonvoiding contractions (NVC). AboBoNTA 22.5 U significantly decreased maximal pressure, without affecting voiding efficiency. Injected in four sites, aboBoNTA significantly increased bladder capacity and compliance while only the latter when in eight sites. AboBoNTA significantly reduced NVC frequency and amplitude. This preclinical investigation showed similar inhibiting effects of aboBoNTA despite the number of sites reduction. Further studies are warranted to optimize dosing schemes to improve the risk-benefit ratio of BoNTA-based treatment modalities for NDO and further idiopathic overactive bladder. 相似文献